Biopharmaceutical "Twelfth Five Year Plan" to be released next month

According to Yu Mingde, president of the China Association of Pharmaceutical Enterprise Management, the 12th Five-Year Plan for Chinese medical biology is expected to be officially released in December. The general contents of the plan have been clarified, and only some of the contents need to be revised.

He disclosed that the plan did not particularly emphasize the development speed of the biopharmaceutical industry, but focused on "transition" and "upgrade". The plan includes specific support policies for the pharmaceutical preparation industry, modern Chinese medicine, and innovative drugs. It also defines many support plans and projects to complete the "Twelfth Five-Year Plan" industry goals.

Regarding the news that the "medicine price management measures" that were introduced in the original year had been postponed until next year, Yu Mingde said that no relevant official documents have been seen for the time being. This news made the biomedicine sector surged 2.61% at the same time as all A shares fell 0.47% on November 9.

For the determination of the price of essential drugs, Yu Mingde does not advocate the rise in drug prices, but does not agree that the irrationality of drug prices falls. For example, he said that taking the bidding for essential drugs in Anhui Province as an example, the vicious competition among pharmaceutical companies and the bids below the cost price are not conducive to the sustained development of the industry.

For Chinese herbal medicines prices have continued to rise this year, he believes that the cost rises. If the price of Chinese herbal medicines is suppressed, it is unreasonable for many companies, and companies should not be allowed to independently absorb all cost pressures. He said that despite the fact that the system of "taking medicine to support medicine" has not yet been eliminated, the market mechanism is temporarily difficult to fully play its role in the status quo of hospital monopolies, making it difficult for the drug prices to be determined by the market. In the future, it should adhere to the principle of market-based drug pricing.